JPH08510240A - Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ - Google Patents

Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ

Info

Publication number
JPH08510240A
JPH08510240A JP6525508A JP52550894A JPH08510240A JP H08510240 A JPH08510240 A JP H08510240A JP 6525508 A JP6525508 A JP 6525508A JP 52550894 A JP52550894 A JP 52550894A JP H08510240 A JPH08510240 A JP H08510240A
Authority
JP
Japan
Prior art keywords
amino acid
hcv
antibody
motif
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6525508A
Other languages
English (en)
Japanese (ja)
Inventor
ジェイ． ウェイナー，エイミー
ホートン，マイケル
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22037528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH08510240(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JPH08510240A publication Critical patent/JPH08510240A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C07K16/118—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP6525508A 1993-05-12 1994-05-03 Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ Pending JPH08510240A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6169993A 1993-05-12 1993-05-12
US08/061,699 1993-05-12
PCT/US1994/004853 WO1994026306A1 (en) 1993-05-12 1994-05-03 Conserved motif of hepatitis c virus e2/ns1 region

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2004347900A Division JP2005097319A (ja) 1993-05-12 2004-11-30 Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
JP2005152406A Division JP2005325126A (ja) 1993-05-12 2005-05-25 Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ

Publications (1)

Publication Number Publication Date
JPH08510240A true JPH08510240A (ja) 1996-10-29

Family

ID=22037528

Family Applications (3)

Application Number Title Priority Date Filing Date
JP6525508A Pending JPH08510240A (ja) 1993-05-12 1994-05-03 Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
JP2004347900A Withdrawn JP2005097319A (ja) 1993-05-12 2004-11-30 Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
JP2005152406A Withdrawn JP2005325126A (ja) 1993-05-12 2005-05-25 Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2004347900A Withdrawn JP2005097319A (ja) 1993-05-12 2004-11-30 Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
JP2005152406A Withdrawn JP2005325126A (ja) 1993-05-12 2005-05-25 Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ

Country Status (7)

Country Link
US (6) US6692907B1 (enExample)
EP (2) EP0697888B1 (enExample)
JP (3) JPH08510240A (enExample)
AT (1) ATE249838T1 (enExample)
CA (1) CA2162557C (enExample)
DE (1) DE69433160T2 (enExample)
WO (1) WO1994026306A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515249A (ja) * 1998-05-19 2002-05-28 インスティトゥト ディ リチェルケ ディ ビオロジア モレコラーレ ピー．アンジェレッティ ソチエタ ペル アツィオニ Ｈｃｖのｅ２糖タンパク質の超可変部１のミモトープおよびその使用
JP2003514872A (ja) * 1999-11-19 2003-04-22 シーエスエル、リミテッド ワクチン組成物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0697888B1 (en) * 1993-05-12 2003-09-17 Chiron Corporation Conserved motif of hepatitis c virus e2/ns1 region
DE19504302A1 (de) * 1995-02-09 1996-08-14 Boehringer Mannheim Gmbh Methode zur serologischen Typisierung mittels typspezifischer Antigene
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
KR970065713A (ko) * 1996-03-19 1997-10-13 성재갑 C형 간염 바이러스(일본형)의 분비형 외피 단백질 1 및 2
AU7602800A (en) * 1999-09-23 2001-04-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
WO2001058459A1 (fr) * 2000-02-14 2001-08-16 Mitsubishi Pharma Corporation Remedes contre l'hepatite c
US20110097332A1 (en) * 2007-08-06 2011-04-28 Martina Buck Composition and Method of Use for HCV Immunization
US8314371B2 (en) 2008-11-06 2012-11-20 Applied Materials, Inc. Rapid thermal processing chamber with micro-positioning system
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146633A (en) * 1973-05-07 2000-11-14 The Ohio State University Method for treatment of antigenically modified polypeptides
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
CA1188985A (en) * 1980-07-01 1985-06-18 Edward J. Stott Production of viral antigens
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0164556B1 (en) 1984-05-11 1994-03-02 Chiron Corporation Enhanced yeast transcription employing hybrid promoter region constructs
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
CN1074422C (zh) 1987-11-18 2001-11-07 希龙股份有限公司 制备含有hcv表位的分离多肽的方法
US5252459A (en) 1988-09-23 1993-10-12 Abbott Laboratories Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
HUT54896A (en) * 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
HUT59964A (en) 1989-05-18 1992-07-28 Chiron Corp Process for producing new nanbv diagnostica for determining hepatitis c virus
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5308750A (en) * 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
EP0842947B2 (en) * 1990-11-08 2009-03-18 Novartis Vaccines and Diagnostics, Inc. Hepatitis C virus asialoglycoproteins
US5574132A (en) 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
WO1993000365A2 (en) 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
WO1993006126A1 (en) * 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
EP0583481B1 (en) 1992-02-05 1999-11-10 Daikin Industries, Ltd. Polytetrafluoroethylene powder for molding
US5891640A (en) 1992-03-06 1999-04-06 N.V. Innogenetics S.A. Peptide derived from human immunodeficiency virus type 1 (HIV-1), isolate ant70, containing an immunodominant epitope and it's use in immunodiagnostic assays
EP0697888B1 (en) * 1993-05-12 2003-09-17 Chiron Corporation Conserved motif of hepatitis c virus e2/ns1 region
EP0992580B1 (en) 1993-11-04 2005-03-09 Innogenetics N.V. Immunodominant human T-cell epitopes of Hepatitis C virus
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
MXPA02012401A (es) * 2000-06-15 2003-04-25 Chiron Corp Inmunoensayos para anticuerpos anti-virus de hepatitis c.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515249A (ja) * 1998-05-19 2002-05-28 インスティトゥト ディ リチェルケ ディ ビオロジア モレコラーレ ピー．アンジェレッティ ソチエタ ペル アツィオニ Ｈｃｖのｅ２糖タンパク質の超可変部１のミモトープおよびその使用
JP2003514872A (ja) * 1999-11-19 2003-04-22 シーエスエル、リミテッド ワクチン組成物

Also Published As

Publication number Publication date
DE69433160T2 (de) 2004-07-08
US20070014813A1 (en) 2007-01-18
CA2162557C (en) 2004-09-28
WO1994026306A1 (en) 1994-11-24
US7371386B2 (en) 2008-05-13
US7252827B1 (en) 2007-08-07
JP2005325126A (ja) 2005-11-24
US20030017156A1 (en) 2003-01-23
JP2005097319A (ja) 2005-04-14
US7135185B1 (en) 2006-11-14
US6692907B1 (en) 2004-02-17
EP0697888A1 (en) 1996-02-28
CA2162557A1 (en) 1994-11-24
DE69433160D1 (de) 2003-10-30
ATE249838T1 (de) 2003-10-15
US7098303B1 (en) 2006-08-29
EP0697888B1 (en) 2003-09-17
EP1421951A3 (en) 2005-10-05
EP1421951A2 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
FI112438B (fi) DNA-molekyyli ja menetelmä hepatiitti C-viruksen vastaisten vasta-aineiden ilmaisemiseksi
CA2110058C (en) Hepatitis c virus (hcv) polypeptides
KR970010925B1 (ko) Hcv 펩티드-항원 및 c형 간염 바이러스(hcv)의 검사 방법
HU227275B1 (en) Particles of hcv envelope proteins: use for vaccination
JPH08510240A (ja) Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
Zucchelli et al. Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross‐reactive antibody response by genetic immunization
JP2598245B2 (ja) Ｈｔｌｖ−ｉｉｉ／ｌａｖウイルス関連ペプチドに対する抗体
US5639594A (en) Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis
US4857634A (en) Peptides useful in vaccination against enteroviruses
EP1002092A1 (en) Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
CN1082053A (zh) 合成多肽
EP0175613A2 (en) Immunogenic hav peptides
PT671946E (pt) Peptidos imunorreactivos do virus epstein-barr
DE69017352T2 (de) An HIV relatierte Peptide.
CA1287447C (en) Peptides useful in vaccination against enteroviruses
EA004228B1 (ru) МОДУЛЯТОР ИММУННОГО ОТВЕТА α- МАКРОГЛОБУЛИНОВЫЙ КОМПЛЕКС

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040830

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20041018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050622

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20050804

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20050818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080129